MetaCap

Adicet Bio (ACET) vs TherapeuticsMD (TXMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

TherapeuticsMD (TXMD) has outperformed Adicet Bio (ACET) over the past year, losing 3.9% versus a loss of 77.8%. Over five years, TXMD leads with a -94.1% price change compared with -98.6% for ACET. Adicet Bio is the larger company by market cap ($20.0 million vs $19.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACET-77.78%TXMD-3.93%
+62%-11%-84%
Nov 21, 20251 yearNov 20, 2026
ACET-98.56%TXMD-94.00%
+140%+15%-110%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACET versus TXMD key metrics
MetricACETTXMD
Share price$2.14$1.71
Market cap$20.03M$19.79M
1-day change-13.01%-5.52%
YTD return-74.58%+4.91%
1-year return-77.78%-3.93%
5-year return-98.58%-94.10%
P/E ratio (TTM)—171.00
Forward P/E—4.89
EPS (TTM)$-7.53$0.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$3.02M
Revenue growth (YoY)—+71.61%
Net income (latest FY)$-116.80M$-569.00K
Operating margin—-145.27%
Net margin—-18.83%
52-week high$11.15$2.95
52-week low$2.12$1.43
Distance from 52-week high-80.81%-42.03%
Analyst consensusstrong_buy—
Avg. price target upside+1527.57%—
Average volume271.05K24.50K
Shares outstanding9.36M11.57M
Employees1021
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TXMD has outperformed ACET by 73.8 percentage points over the past year.

About Adicet Bio

ACET stock →

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees

About TherapeuticsMD

TXMD stock →

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

ACET vs TXMD FAQ

Which is bigger, Adicet Bio or TherapeuticsMD?

Adicet Bio (ACET) is larger, with a market capitalization of $20.03M compared with $19.79M for TherapeuticsMD (TXMD).

Which stock has performed better over the past year, ACET or TXMD?

TXMD returned -3.93% over the past 12 months, compared with -77.78% for ACET (price return, excluding dividends). Past performance does not predict future results.

Are Adicet Bio and TherapeuticsMD in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons